Skip to main content

Table 1 Demographic and clinical features for all patients

From: A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma

 

n

%

Gender

  

  Male

31

73.8%

  Female

11

26.2%

Age

  

  ≤ 50 years

20

47.6%

  > 50 years

22

52.4%

Distance from anal verge

  

  ≤ 5 cm

27

64.3%

  > 5 cm

15

35.7%

cT

  

  T3

28

66.7%

  T4

14

33.3%

cN

  

  N0

5

11.9%

  N1

22

52.4%

  N2

15

35.7%

Total

42

100.0%